Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Breast Cancer Research and Treatment
Erschienen in: Breast Cancer Research and Treatment 2/2019

10.10.2018 | Preclinical study

Impact of Topoisomerase IIα, PTEN, ABCC1/MRP1, and KI67 on triple-negative breast cancer patients treated with neoadjuvant chemotherapy

verfasst von: Fouzia Guestini, Katsuhiko Ono, Minoru Miyashita, Takanori Ishida, Noriaki Ohuchi, Saki Nakagawa, Hisashi Hirakawa, Kentaro Tamaki, Yasuyo Ohi, Yoshiaki Rai, Yasuaki Sagara, Hironobu Sasano, Keely May McNamara

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Triple-negative breast cancer (TNBC) patients with residual disease following neoadjuvant chemotherapy (NAC) harbor higher risk of relapse, and eventual demise compared to those who achieve pathologic complete response. Therefore, in this study, we assessed a panel of molecules involved in key pathways of drug resistance and tumor progression before and after NAC in TNBC patients, in order to clarify the underlying mechanisms.

Methods

We studied 148 TNBC Japanese patients treated with anthracycline/taxane-based NAC. KI67, Topoisomerase IIα (TopoIIα), PTEN, p53, Bcl2, vimentin, ABCG2/BCRP1, ABCB1/MDR1, and ABCC1/MRP1 were immunolocalized in surgical pathology materials before and after NAC.

Results

The status of vimentin and increasing labeling index (LI) of TopoIIα and KI67 in biopsy specimens were significantly associated with those who responded to NAC treatment. The abundance of p53 (p = 0.003), ABCC1/MRP1 (p = 0.033), ABCB1/MDR1 (p = 0.022), and a loss of PTEN (p < 0.0001) in surgery specimens following treatment were associated with pathologic parameters. TopoIIα, PTEN, and ABCC1/MRP1 status predicted pathologic response. In addition, the status of PTEN, ABCC1/MRP1, ABCB1/MDR1, Bcl2, and vimentin in surgical specimens was also significantly associated with adverse clinicopathological factors in surgery specimens, suggesting that these alterations could be responsible for tumor relapse in TNBC patients.

Conclusion

KI67, TopoIIα, PTEN, and ABCC1/MRP1 status could predict treatment response and/or eventual clinical outcomes. These results could also provide an insight into the mechanisms of drug resistance and relapse of TNBC patients receiving NAC.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, Cristofanilli M, Hortobagyi GN, Pusztai L (2008) Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26(8):1275–1281CrossRef
2.
3.
Martin M, Romero A, Cheang MCU, Lopez Garcıa-Asenjo JU, Garcıa-Saenz JA, Oliva B, Roman JM, He X, Casado A, de la Torre J, Furio J, Puente J, Caldes T, Vidart JA, Lopez-Tarruella S, Diaz-Rubio E, Perou CM (2011) Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer. Breast Cancer Res Treat 128:127–136CrossRef
4.
Wahba HA, El-Hadaad HA (2015) Current approaches in treatment of triple-negative breast cancer. Cancer Biol Med 12(2):106–116PubMedPubMedCentral
5.
Székely B, Silber AL, Pusztai L (2017) New therapeutic strategies for triple-negative breast cancer. Oncology 31(2):130–137
6.
Zhang LH, Yang AJ, Wang M, Liu W, Wang CY, Xie XF, Chen X, Dong JF, Li M (2016) Enhanced autophagy reveals vulnerability of P-gp mediated epirubicin resistance in triple negative breast cancer cells. Apoptosis 21(4):473–488
7.
Yamada A, Ishikawa T, Ota I, Kimura M, Shimizu D, Tanabe M, Chishima T, Sasaki T, Ichikawa Y, Morita S, Yoshiura K, Takabe K, Endo I (2013) High expression of ATP-binding cassette transporter ABCC11 in breast tumors is associated with aggressive subtypes and low disease-free survival. Breast Cancer Res Treat 137(3):773–782CrossRef
8.
Xu H, Eirew P, Mullaly SC, Aparicio S (2014) The omics of triple-negative breast cancers. Clin Chem 60(1):122–133CrossRef
9.
10.
O’Reilly EA, Gubbins L, Sharma S, Tully R, Ho Zhing Guang M, Weiner-Gorzel W, McCaffrey J, Harrison M, Furlong F, Kell M, McCanna A (2015) The fate of chemoresistance in triple negative breast cancer (TNBC). BBA Clin 3:257–275CrossRef
11.
Bouchalova K, Cizkova M, Cwiertka K, Trojanec R, Hajduch M (2009) Triple negative breast cancer-current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 153(1):13–17CrossRef
12.
Balko JM, Giltnane JM, Wang K, Schwarz LJ (2014) Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer Discov 4(2):232–245CrossRef
13.
Lonning PE, Knappskog S (2013) Mapping genetic alterations causing chemoresistance in cancer: identifying the roads by tracking the drivers. Oncogene 32(46):5315–5330CrossRef
14.
McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2005) Reporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 93(4):387–391CrossRef
15.
Davis SL, Eckhardt SG, Tentler JJ, Diamond JR (2014) Triple-negative breast cancer: bridging the gap from cancer genomics to predictive biomarkers. Ther Adv Med Oncol 6(3):88–100CrossRef
16.
Lehmann BD, Pietenpol JA (2014) Identification and use of biomarkers in treatment strategies for triple negative breast cancer subtypes. J Pathol 232(2):142–150CrossRef
17.
Guestini F, McNamara KM, Ishida T, Sasano H (2016) Triple negative breast cancer chemosensitivity and chemoresistance: current advances in biomarkers identification. Exp Opin Ther Targets 20(6):705–720CrossRef
18.
Yadav BS, Chanana P, Jhamb S (2015) Biomarkers in triple negative breast cancer: a review. World J Clin Oncol 6(6):252–263CrossRef
19.
Fleisher B, Clarke C, Ait-Oudhia S (2016) Current advances in biomarkers for targeted therapy in triple-negative breast cancer. Breast Cancer 8:183–197
20.
Longley DB, Johnston PG (2005) Molecular mechanisms of drug resistance. J Pathol 205(2):275–292CrossRef
21.
22.
Ossovskaya V, Wang Y, Budoff A, Xu Q, Lituev A, Potapova O, Vansant G, Monforte J, Daraselia N (2011) Exploring molecular pathways of triple-negative breast cancer. Genes Cancer 2(9):870–879CrossRef
23.
Lips EH, Michaut M, Hoogstraat M, Mulder L, Besselink NJM, Koudijs MJ, Cuppen E, Voest EE, Bernards R, Nederlof PM, Wesseling J, Rodenhuis S, Wessels LFA (2015) Next generation sequencing of triple negative breast cancer to find predictors for chemotherapy response. Breast Cancer Res 17(1):134PubMedPubMedCentralCrossRef
24.
Chen Y-H, Hancock BA, Solzak JP, Brinza D, Scafe C, Miller KD, Radovich M (2017) Next-generation sequencing of circulating tumor DNA to predict recurrence in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy. NPJ Breast Cancer 3(1):24PubMedPubMedCentralCrossRef
25.
Santuario-Facio SK, Cardona-Huerta S, Perez-Paramo YX, Trevino V, Hernandez-Cabrera F, Rojas-Martinez A, Uscanga-Perales G, Martinez-Rodriguez JL, Martinez-Jacobo L, Padilla-Rivas G et al (2017) A new gene expression signature for triple-negative breast cancer using frozen fresh tissue before neoadjuvant chemotherapy. Mol Med 23:101–111CrossRef
26.
Wein L, Loi S (2017) Mechanisms of resistance of chemotherapy in early-stage triple negative breast cancer (TNBC). Breast 34(Suppl 1):S27–S30
27.
Bareche Y, Venet D, Ignatiadis M, Aftimos P, Piccart M, Rothe F, Sotiriou C (2018) Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis. Ann Oncol 29:895–902CrossRef
28.
Kim T, Han W, Kim MK, Lee JW, Kim J, Ahn SK, Lee H-B, Moon H-G, Lee K-H, Kim T-Y et al (2015) Predictive significance of p53, Ki-67, and Bcl-2 expression for pathologic complete response after neoadjuvant chemotherapy for triple-negative breast cancer. J Breast Cancer 18(1):16–21
29.
Wang W, Wu J, Zhang P, Fei X, Zong Y, Chen X, Huang O, He J-R, Chen W, Li Y et al (2016) Prognostic and predictive value of Ki-67 in triple-negative breast cancer. Oncotarget 7(21):31079–31087
30.
Elnemr GM, El-Rashidy AH, Osman AH, Issa LF, Abbas OA, Al-Zahrani AS, El-Seman SM, Mohammed AA, Hassan AA (2016) Response of triple negative breast cancer to neoadjuvant chemotherapy: correlation between Ki-67 expression and pathological response. Asian Pac J Cancer Prev 17(2):807–813CrossRef
31.
Nakashoji A, Matsui A, Nagayama A, Iwata Y, Sasahara M, Murata Y (2017) Clinical predictors of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer. Oncol Lett 14(4):4135–4141CrossRef
32.
Nogi H, Uchida KEN, Kamio M, Kato K, Toriumi Y, Akiba T, Morikawa T, Suzuki M, Kobayashi T, Takeyama H (2016) Triple-negative breast cancer exhibits a favorable response to neoadjuvant chemotherapy independent of the expression of Topoisomerase IIα. Mol Clin Oncol 4(3):383–389
33.
Li XY, Mu L, Feng J (2016) Topoisomerase IIα and BRCA1 expression as predictive factors for anthracycline-based adjuvant chemotherapy response and prognosis in triple-negative breast cancers. Int J Clin Exp Pathol 9(9):9249–9258
34.
Ignatiadis M, Singhal SK, Desmedt C, Haibe-Kains B, Criscitiello C, Andre F, Loi S, Piccart M, Michiels S, Sotiriou C (2012) Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis. J Clin Oncol 30(16):1996–2004CrossRef
35.
36.
Abdel-Fatah TM, Perry C, Dickinson P, Ball G, Moseley P, Madhusudan S, Ellis IO, Chan SY (2013) Bcl2 is an independent prognostic marker of triple negative breast cancer (TNBC) and predicts response to anthracycline combination (ATC) chemotherapy (CT) in adjuvant and neoadjuvant settings. Ann Oncol 24(11):2801–2807CrossRef
37.
Karihtala P, Auvinen P, Kauppila S, Haapasaari KM, Jukkola-Vuorinen A, Soini Y (2013) Vimentin, zeb1 and Sip1 are up-regulated in triple-negative and basal-like breast cancers: association with an aggressive tumour phenotype. Breast Cancer Res Treat 138(1):81–90CrossRef
38.
Yamashita N, Tokunaga E, Kitao H, Hisamatsu Y, Taketani K, Akiyoshi S, Okada S, Aishima S, Morita M, Maehara Y (2013) Vimentin as a poor prognostic factor for triple-negative breast cancer. J Cancer Res Clin Oncol 139(5):739–746CrossRef
39.
Wang L, Jiang Z, Sui M, Shen J, Xu C, Fan W (2009) The potential biomarkers in predicting pathologic response of breast cancer to three different chemotherapy regimens: a case control study. BMC Cancer 9:226–226
40.
Kovalev AA, Tsvetaeva DA, Grudinskaja TV (2013) Role of ABC-cassette transporters (MDR1, MRP1, BCRP) in the development of primary and acquired multiple drug resistance in patients with early and metastatic breast cancer. Exp Oncol 35(4):287–290
41.
Delou JMdA, Vignal GM, Índio-do-Brasil V, Accioly MTdS, da Silva TSL, Piranda DN, Sobral-Leite M, de Carvalho MA, Capella MAM, Vianna-Jorge R (2017) Loss of constitutive ABCB1 expression in breast cancer associated with worse prognosis. Breast Cancer 9:415–428
42.
Eisenhauera EA, Therasseb P, Bogaertsc J, Schwartzd LH, Sargente D, Fordf R, Danceyg J, Arbuckh S, Gwytheri S, Mooneyg M, Rubinsteing L, Shankarg L, Doddg L, Kaplanj R, Lacombec D, Verweijk J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247
43.
Leslie EM, Deeley RG, Cole SP (2005) Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol 204(3):216–237CrossRef
44.
Kim B, Fatayer H, Hanby AM, Horgan K, Perry SL, Valleley EM, Verghese ET, Williams BJ, Thorne JL, Hughes TA (2013) Neoadjuvant chemotherapy induces expression levels of breast cancer resistance protein that predict disease-free survival in breast cancer. PLoS ONE 8(5):e62766PubMedPubMedCentralCrossRef
45.
Collina F, Di Bonito M, Li Bergolis V, De Laurentiis M, Vitagliano C, Cerrone M, Nuzzo F, Cantile M, Botti G (2015) Prognostic value of cancer stem cells markers in triple-negative breast cancer. Biomed Res Int 2015:158682PubMedPubMedCentralCrossRef
46.
Chen Z-S, Tiwari AK (2011) Multidrug resistance proteins (MRPs/ABCCs) in cancer chemotherapy and genetic diseases. FEBS J 278(18):3226–3245CrossRef
47.
Kathawala RJ, Gupta P, Ashby CR, Chen ZS (2015) The modulation of ABC transporter-mediated multidrug resistance in cancer: a review of the past decade. Drug Resist Updates 18:1–17CrossRef
48.
Zhang L-h, Yang A-j, Wang M, Liu W, Wang C-y, Xie X-f, Chen X, Dong J-f, Li M (2016) Enhanced autophagy reveals vulnerability of P-gp mediated epirubicin resistance in triple negative breast cancer cells. Apoptosis 21(4):473–488
49.
Lehmann BD, Jovanovic B, Chen X, Estrada MV, Johnson KN, Shyr Y, Moses HL, Sanders ME, Pietenpol JA (2016) Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection. PLoS ONE 11(6):e0157368PubMedPubMedCentralCrossRef
50.
Jang MH, Kim HJ, Kim EJ, Chung YR, Park SY (2015) Expression of epithelial-mesenchymal transition-related markers in triple-negative breast cancer: ZEB1 as a potential biomarker for poor clinical outcome. Hum Pathol 46(9):1267–1274CrossRef
51.
Tawfik K, Kimler BF, Davis MK, Fan F, Tawfik O (2012) Prognostic significance of Bcl-2 in invasive mammary carcinomas: a comparative clinicopathologic study between “triple-negative” and non-“triple-negative” tumors. Hum Pathol 43(1):23–30CrossRef
52.
Hwang KT, Woo JW, Shin HC, Kim HS, Ahn SK, Moon HG, Han W, Park IA, Noh DY (2012) Prognostic influence of BCL2 expression in breast cancer. Int J Cancer 131(7):E1109–E1119CrossRef
53.
Vargas-Roig LM, Cuello-Carrión FD, Fernández-Escobar N, Daguerre P, Leuzzi M, Ibarra J, Gago FE, Nadin SB, Ciocca DR (2008) Prognostic value of Bcl-2 in breast cancer patients treated with neoadjuvant anthracycline based chemotherapy. Mol Oncol 2(1):102–111CrossRef
54.
55.
Guestini F, McNamara KM, Sasano H (2017) The use of chemosensitizers to enhance the response to conventional therapy in triple-negative breast cancer patients. Breast Cancer Manag 6(4):127–131CrossRef
56.
Hu Y, Yague E, Zhao J, Wang L, Bai J, Yang Q, Pan T, Zhao H, Liu J, Zhang J (2018) Sabutoclax, pan-active BCL-2 protein family antagonist, overcomes drug resistance and eliminates cancer stem cells in breast cancer. Cancer Lett 423:47–59CrossRef
57.
Yndestad S, Austreid E, Knappskog S, Chrisanthar R, Lilleng PK, Lonning PE, Eikesdal HP (2017) High PTEN gene expression is a negative prognostic marker in human primary breast cancers with preserved p53 function. Breast Cancer Res Treat 163(1):177–190CrossRef
58.
Brandmaier A, Hou SQ, Shen WH (2017) Cell cycle control by PTEN. J Mol Biol 429(15):2265–2277CrossRef
59.
Wang X, Jiang X (2008) Post-translational regulation of PTEN. Oncogene 27(41):5454–5463CrossRef
60.
61.
Iqbal J, Thike AA, Cheok PY, Tse GM, Tan PH (2012) Insulin growth factor receptor-1 expression and loss of PTEN protein predict early recurrence in triple-negative breast cancer. Histopathology 61(4):652–659CrossRef
62.
Inanc M, Ozkan M, Karaca H, Berk V, Bozkurt O, Duran AO, Ozaslan E, Akgun H, Tekelioglu F, Elmali F (2014) Cytokeratin 5/6, c-Met expressions, and PTEN loss prognostic indicators in triple-negative breast cancer. Med Oncol 31(1):801PubMedCrossRef
63.
Beg S, Siraj AK, Prabhakaran S, Jehan Z, Ajarim D, Al-Dayel F, Tulbah A, Al-Kuraya KS (2015) Loss of PTEN expression is associated with aggressive behavior and poor prognosis in Middle Eastern triple-negative breast cancer. Breast Cancer Res Treat 151(3):541–553CrossRef
64.
Li S, Shen Y, Wang M, Yang J, Lv M, Li P, Chen Z, Yang J (2017) Loss of PTEN expression in breast cancer: association with clinicopathological characteristics and prognosis. Oncotarget 8(19):32043–32054
65.
Fouque A, Jean M, Weghe PV, Legembre P (2016) Review of PI3K/mTOR inhibitors entering clinical trials to treat triple negative breast cancers. Recent Pat Anticancer Drug Discov 11(3):283–296CrossRef
66.
67.
Massihnia D, Galvano A, Fanale D, Perez A, Castiglia M, Incorvaia L, Listi A, Rizzo S, Cicero G, Bazan V, Castorina S, Russo A (2016) Triple negative breast cancer: shedding light onto the role of PI3K/Akt/mTOR pathway. Oncotarget 7(37):60712–60722CrossRef
68.
Kang X, Song C, Du X, Zhang C, Liu Y, Liang L, He J, Lamb K, Shen WH, Yin Y (2015) PTEN stabilizes TOP2A and regulates the DNA decatenation. Sci Rep 5:17873PubMedPubMedCentralCrossRef
69.
Yuan L, Lv Y, Li H, Gao H, Song S, Zhang Y, Xing G, Kong X, Wang L, Li Y, Zhou T, Gao D, Xiao ZX, Yin Y, Wei W, He F, Zhang L (2015) Deubiquitylase OTUD3 regulates PTEN stability and suppresses tumorigenesis. Nat Cell Biol 17:1169PubMedCrossRef
70.
71.
Millis SZ, Gatalica Z, Winkler J, Vranic S, Kimbrough J, Reddy S, O’Shaughnessy JA (2015) Predictive biomarker profiling of > 6000 breast cancer patients shows heterogeneity in TNBC, with treatment implications. Clin Breast Cancer 15(6):473–481CrossRef
72.
Zeichner SB, Terawaki H, Gogineni K (2016) A review of systemic treatment in metastatic triple-negative breast cancer. Breast Cancer 10:25–36
73.
Keam B, Im SA, Lee KH, Han SW, Oh DY, Kim JH, Lee SH, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Bang YJ (2011) Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. Breast Cancer Res 13(2):R22PubMedPubMedCentralCrossRef
74.
Li XR, Liu M, Zhang YJ, Wang JD, Zheng YQ, Li J, Ma B, Song X (2011) CK5/6, EGFR, Ki-67, cyclin D1, and nm23-H1 protein expressions as predictors of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer patients. Med Oncol 28(Suppl 1):S129–S134
75.
Tan QX, Qin QH, Yang WP, Mo QG, Wei CY (2014) Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy. Int J Clin Exp Pathol 7(10):6862–6870
76.
Tian M, Zhong Y, Zhou F, Xie C, Zhou Y, Liao Z (2015) Effect of neoadjuvant chemotherapy in patients with triple-negative breast cancer: a meta-analysis. Oncol Lett 9(6):2825–2832CrossRef
77.
78.
Wang J, Xu B, Yuan P, Zhang P, Li Q, Ma F, Fan Y (2012) TOP2A amplification in breast cancer is a predictive marker of anthracycline-based neoadjuvant chemotherapy efficacy. Breast Cancer Res Treat 135(2):531–537CrossRef
79.
Bravaccini S, Rocca A, Bronte G (2018) Is Ki67 still a powerful ally in predicting the clinical benefit of anthracyclines for the adjuvant treatment of early breast cancer? Breast Cancer Res Treat 168:767–768CrossRef
80.
Rossi L, Laas E, Mallon P, Vincent-Salomon A, Guinebretiere JM, Lerebours F, Rouzier R, Pierga JY, Reyal F (2015) Prognostic impact of discrepant Ki67 and mitotic index on hormone receptor-positive, HER2-negative breast carcinoma. Br J Cancer 113:996PubMedPubMedCentralCrossRef
81.
Mueller RE, Parkes RK, Andrulis I, O’Malley FP (2004) Amplification of the TOP2A gene does not predict high levels of Topoisomerase II alpha protein in human breast tumor samples. Genes Chromosom Cancer 39:288–297CrossRef
82.
Khan F, Esnakula A, Ricks-Santi LJ, Zafar R, Kanaan Y, Naab T (2018) Loss of PTEN in high grade advanced stage triple negative breast ductal cancers in African American women. Pathology 214(5):673–678
83.
Dillon LM, Miller TW (2014) Therapeutic targeting of cancers with loss of PTEN function. Curr Drug Targets 15(1):65–79CrossRef
84.
Darb-Esfahani S, Denkert C, Stenzinger A, Salat C, Sinn B, Schem C, Endris V, Klare P, Schmitt W, Blohmer J-U et al (2016) Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy. Oncotarget 7(42):67686–67698CrossRef
85.
Yamashita H, Toyama T, Nishio M, Ando Y, Hamaguchi M, Zhang Z, Kobayashi S, Fujii Y, Iwase H (2006) p53 protein accumulation predicts resistance to endocrine therapy and decreased post-relapse survival in metastatic breast cancer. Breast Cancer Res 8(4):R48PubMedPubMedCentralCrossRef
86.
Varga Z, Cassoly E, Li Q, Oehlschlegel C, Tapia C, Lehr HA, Klingbiel D, Thürlimann B, Ruhstaller T (2015) Standardization for Ki-67 assessment in moderately differentiated breast cancer. A retrospective analysis of the SAKK 28/12 study. PLoS ONE 10(4):e0123435PubMedPubMedCentralCrossRef
87.
Biesaga B, Niemiec J, Ziobro M (2014) BCL-2, Topoisomerase IIα, microvessel density and prognosis of early advanced breast cancer patients after adjuvant anthracycline-based chemotherapy. J Cancer Res Clin Oncol 140:2009–2019CrossRef
88.
Gonzalez-Angulo AM, Ferrer-Lozano J, Stemke-Hale K, Sahin A, Liu S, Barrera JA, Burgues O, Lluch AM, Chen H, Hortobagyi GN, Mills GB, Meric-Bernstam F (2011) PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer. Mol Cancer Ther 10(6):1093–1101CrossRef
89.
90.
Soini Y, Jarvinen K, Kaarteenaho Wiik R, Kinnula V (2001) The expression of P-glycoprotein and multidrug resistance proteins 1 and 2 (MRP1 and MRP2) in human malignant mesothelioma. Ann Oncol 12:1239–1245CrossRef
Metadaten
Titel
Impact of Topoisomerase IIα, PTEN, ABCC1/MRP1, and KI67 on triple-negative breast cancer patients treated with neoadjuvant chemotherapy
verfasst von
Fouzia Guestini
Katsuhiko Ono
Minoru Miyashita
Takanori Ishida
Noriaki Ohuchi
Saki Nakagawa
Hisashi Hirakawa
Kentaro Tamaki
Yasuyo Ohi
Yoshiaki Rai
Yasuaki Sagara
Hironobu Sasano
Keely May McNamara
Publikationsdatum
10.10.2018
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 2/2019
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-018-4985-6

Weitere Artikel der Ausgabe 2/2019

Breast Cancer Research and Treatment 2/2019 Zur Ausgabe

Review

One year versus a shorter duration of adjuvant trastuzumab for HER2-positive early breast cancer: a systematic review and meta-analysis

Epidemiology

Which patients with sentinel node-positive breast cancer after breast conservation still receive completion axillary lymph node dissection in routine clinical practice?

Epidemiology

The influence of reconstruction choice and inclusion of radiation therapy on functional shoulder biomechanics in women undergoing mastectomy for breast cancer

Clinical trial

Metronomic capecitabine combined with aromatase inhibitors for new chemoendocrine treatment of advanced breast cancer: a phase II clinical trial

Clinical trial

A randomized trial of interpersonal psychotherapy, problem solving therapy, and supportive therapy for major depressive disorder in women with breast cancer

Clinical trial

High patient satisfaction with a simplified BRCA1/2 testing procedure: long-term results of a prospective study

Neu im Fachgebiet Onkologie

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

ICI-Therapie in der Schwangerschaft wird gut toleriert

22.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Krebspatienten impfen: Was? Wen? Und wann nicht?

22.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Müde im Alter? Auch an die Nebenniere denken

22.04.2024 | Prostatakarzinom | Nachrichten

Stufenschema weist Prostatakarzinom zuverlässig nach
weitere anzeigen

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen